Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022 – CBI
Homepage /  Press Release /  Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022

Press Release

Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022